Results 231 to 240 of about 22,252 (260)

Clinical efficacy of echinocandin antifungals

Current Opinion in Infectious Diseases, 2001
The prevalence of fungal infections has increased significantly over the past few decades. Candida and Aspergillus spp. are the most common fungal pathogens due to recent changes in medical technology. Amphotericin B continues to be the treatment of choice in many severe disseminated mycosis cases, but problems with toxicity, resistance and non ...
openaire   +2 more sources

Echinocandin antifungals: review and update

Expert Review of Anti-infective Therapy, 2006
The echinocandins are a new and unique class of antifungal agents that act on the fungal cell wall by way of noncompetitive inhibition of the synthesis of 1,3-beta-glucans. All agents of this class are of parenteral formulation, with no oral preparations available.
openaire   +2 more sources

Echinocandins

2022
Malini R. Capoor, Abhijit M. Bal
openaire   +1 more source

Molecular Detection of Resistance to Echinocandins

2016
In the last years, life-threatening fungal diseases have increased significantly, due to the rising number of human individuals susceptible to fungal infections, which are in part complicated by the emergence of antifungal drug-resistant pathogens.
Posteraro, Brunella, Vella, Antonietta, De Carolis, Elena, Sanguinetti, Maurizio   +3 more
openaire   +2 more sources

Anidulafungin, a New Echinocandin

Drugs, 2009
Anidulafungin is a new echinocandin with potent in vitro activity against Aspergillus and Candida species, including those resistant to fluconazole and amphotericin B. Results of several clinical trials indicate that anidulafungin is effective in treating oesophageal candidiasis, including azole-refractory disease.
openaire   +3 more sources

Echinocandins

2021
Alexander J. Lepak, David R. Andes
openaire   +1 more source

Echinocandins

2009
David S. Perlin, William W. Hope
openaire   +1 more source

Echinocandins

Infectious Diseases in Clinical Practice, 2005
openaire   +1 more source

[Echinocandins: Applied pharmacology].

Revista iberoamericana de micologia, 2017
The echinocandins share pharmacodynamic properties, although there are some interesting differences in their pharmacokinetic behaviour in the clinical practice. They are not absorbed by the oral route. They have a somewhat special distribution in the organism, as some of them can reach high intracellular concentrations while, with some others, the ...
openaire   +1 more source

Echinocandins

2010
Andreas H. Groll, Dominik Schrey, Thomas J. Walsh   +2 more
openaire   +1 more source